Insulet announces full market release of Omnipod 5 in Germany

Insulet Corporation announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes in its third market, Germany. Omnipod 5 is also available in the U.S. and the U.K. “We know people in Germany living with type 1 diabetes want the most advanced technology options for making diabetes management easier,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director. “With our impressive data showing improved clinical outcomes from users in the United States over the past year, we are confident in our ability to make a difference in Germany and additional markets in the near future.” Omnipod 5 is the first CE marked tubeless automated insulin delivery system that integrates with the Dexcom G6 Continuous Glucose Monitoring System. The Company’s goal is to make Omnipod 5 available for the majority of Insulet’s European customers by the end of 2024.